Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

Emmenegger, Marc; De Cecco, Elena; Lamparter, David; Jacquat, Raphaël P B; Riou, Julien; Menges, Dominik; Ballouz, Tala; Ebner, Daniel; Schneider, Matthias M; Morales, Itzel Condado; Doğançay, Berre; Guo, Jingjing; Wiedmer, Anne; Domange, Julie; Imeri, Marigona; Moos, Rita; Zografou, Chryssa; Batkitar, Leyla; Madrigal, Lidia; Schneider, Dezirae

doi:10.5167/uzh-228239

Citations

Citation copied

Emmenegger, M., De Cecco, E., Lamparter, D., Jacquat, R. P. B., Riou, J., Menges, D., Ballouz, T., Ebner, D., Schneider, M. M., Morales, I. C., Doğançay, B., Guo, J., Wiedmer, A., Domange, J., Imeri, M., Moos, R., Zografou, C., Batkitar, L., Madrigal, L., … et al. (2023). Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region. IScience, 26, 105928. https://doi.org/10.1016/j.isci.2023.105928

Abstract

Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72'250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 t